846P PHASE III TRIAL OF SUNITINIB (SU) VERSUS PLACEBO (PBO) FOR TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS (NET): IMPACT OF SOMATOSTATIN ANALOGUE (SSA) TREATMENT ON PROGRESSION-FREE SURVIVAL (PFS)